| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Histone deacetylase (HDAC) inhibitors in nature have activity to enhance the gene expression owing to the improvements in the processes of intracellular DNA delivery and intranucleus DNA transcription caused by hyper acetylation of cytosolic microtubules and core histone proteins. We therefore evaluated several types of HDAC inhibitors as enhancer of the gene expression for lipofection. In this study, we developed an efficient formulation for gene therapy in which an HDAC inhibitor, SAHA, is hybridized. The formulation is composed of PEGylated poly-lysine and PEG-SAHA.
|
